AMRN
$15.52
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Intraday
Recent News
How The Amarin (AMRN) Story Is Shifting As Models Rebuild Around The US$12 Target
Amarin’s latest analyst update keeps the price target steady at US$12.00, matching the prior US$12 figure and signaling that the core valuation anchor has not shifted. Analysts are now explaining how their refreshed assumptions still support that US$12.00 level, even as they fine tune the story around revenue trends, margins, and risk. As you read on, you will see how to interpret these moving parts and keep track of how the Amarin narrative evolves from here. Analyst Price Targets don't...
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks
Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death.
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
One is speculative, the other is a reliable blue chip company.